United Therapeutics wins important patent dispute – Yutrepia under pressure with PH-ILD
Reading Time: 3 minutes
United Therapeutics wins an important patent dispute against Liquidia. Yutrepia could lose its PH-ILD approval and might even completely disappear from the US market in the short term. Yutrepia generated $170.4 million in sales in the second quarter. At the same time, United Therapeutics' Tyvaso sales decreased by 4%. By 2027, two potential multi-billion-dollar catalysts, Tyvaso for IPF and Ralinepag for PAH, are awaiting FDA decisions. United Therapeutics (UTHR) develops medications for rare lung and vascular diseases. Its main product...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
